Dear Colleagues:
Now in its 21st year, the NCI-funded T32 Clinical and Translational Cancer Control Research Training Program at the University of Rochester and Wilmot Cancer Institute is seeking outstanding candidates for our upcoming group of post-doctoral fellows starting in summer, 2025.
The program features exceptionally diverse research opportunities and professional guidance by several NCI-funded mentors. Core program mentors include: Drs. Michelle Janelsins, Ph.D., M.P.H., Luke Peppone, Ph.D., M.P.H., Gary Morrow, Ph.D., M.S., Karen Mustian, Ph.D., M.P.H., Supriya Mohile, M.D., M.S., Charles Kamen, Ph.D., M.P.H., Nikesha Gilmore, Ph.D., AnnaLynn Williams, Ph.D., Chin-Shang Li, Ph.D., Paula Cupertino, Ph.D., and Kim Van Orden, Ph.D. An additional 13 affiliate mentors join our core mentors in providing broad multi-disciplinary mentorship experiences for trainees.
Our 4 core training areas are: 1) Phase I-III randomized clinical trials conducted locally and nationwide within the URCC NCORP Research Base, 2) Translational science (e.g., protein biomarker, genetics, epigenetics, immunology, physiology, etc.), 3) Health equity and 4) Biostatistics. Our 4 specialty elective intervention training areas are: 1) exercise oncology, 2) geriatric oncology, 3) nutrition interventions, and 4) psychological interventions. Training in these areas is facilitated by working with one of our specialty laboratories. We also support fellows in other areas of cancer control and supportive cancer care research based on their interests. A more detailed description of the program, description of mentors, current trainees, didactic courses and other research training opportunities, and application materials can be found at: www.futureresearchers.org.
Our program eagerly seeks highly motivated, early-career individuals who recently completed doctorates (Ph.D., M.D., or equivalent) who are committed to developing a successful research career in cancer control as independent investigators. Candidates must be US citizens or permanent residents. Candidates must have completed their doctoral training and have their degree conferred prior to starting the program. Candidates with prior post-doctoral training are also eligible.
Two years of funding with stipends of $70,000 per year are offered along with tuition, the opportunity to receive a Master’s degree, health insurance, childcare costs, research support, travel to scientific meetings, and a Research Assistant Professor position in order to develop a pilot protocol as Principal Investigator. Funding comes from the T32 grant per NIH guidelines and is supplemented by the institution. Applications require three letters of recommendation, a personal statement of your research interests and how you think the program will help your research career along with your CV. Applications received on or before January 15, 2025 will receive priority for review. For questions, please email Co-Directors Drs. Janelsins, Peppone, and Morrow at CancerControlT32@urmc.rochester.edu.
Thank you for your consideration of our NCI T32 Clinical and Translational Cancer Control Research Training Program located in the beautiful Finger Lakes region of upstate New York.
Sincerely,
Michelle Janelsins, Ph.D., M.P.H.
Luke Peppone, Ph.D., M.P.H.
Gary Morrow, Ph.D., M.S.
Co-Directors, Clinical and Translational Cancer Control Research Training Program
